Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for treatment of skin diseases. The company’s pipeline consists of potential novel therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other prevalent severe skin diseases.

Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at several large global pharmaceutical companies and successful start-up biotechs while launching products around the world which achieved billion dollar blockbuster, first-in-class and/or iconic status, such as Prozac®, Gemzar®, Cialis®, Evista®, Taltz®, Humulin®, Cymbalta®, Dysport®, Juvederm® and Kybella®.

Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently under-served dermatology marketplace.


Brickell prides itself on bringing fresh, innovative ideas to the pharmaceutical industry. Our dynamic team strives to provide patients young and old with novel and differentiated therapies for the treatment of skin diseases.


We seek to develop new technologies and differentiated therapeutics to help people with underserved dermatologic conditions. Our current pipeline features novel molecular entities with similar mechanism of actions that will revolutionize the treatment of skin diseases.


We’re intently focused on targeting major opportunities in the global dermatology market. Brickell’s leadership team has a proven track record of success in drug development that backs up this mission.


Brickell deploys resources and energy strategically, maximizing our positive impact on the therapeutic treatment of every patient we treat. We’re able to achieve these results by working with a diverse, well-rounded team featuring a diverse, specialized skill set.


Brickell embodies the power of teamwork. We know when diverse individuals unite and collaborate together in pursuit of a shared vision, the result is vastly more powerful than the sum of its individual parts.


Robert Brown

Chief Executive Officer

Rob Brown joins Brickell as Chief Executive Officer, after having spent over 30 years at Eli Lilly and Company, where he most recently served as chief marketing officer (CMO) and senior vice president of marketing from 2009 through 2018. As CMO, Brown was responsible for building and leading marketing capabilities across Lilly’s pharmaceutical business units, including diabetes, oncology, emerging markets and Lilly Bio-Medicines.

Prior to his role as CMO, Brown held the position of vice president and chief marketing officer for Lilly USA from 2007 - 2009, where he partnered with the business units to ensure Lilly continued to develop industry leading marketing capabilities, streamline and improve marketing processes, and transform marketing by building a consumer marketing center of excellence.

From 2003-2007, Brown was the executive director of marketing for the Intercontinental region, including responsibility for Europe. As the head marketer for Lilly’s international operations, Brown was responsible for the marketing of all Lilly products outside the United States.

Brown previously served as the global marketing director for Cialis and Lilly ICOS, a 50/50 joint venture between Lilly and ICOS Corp from 1999-2003. Brown oversaw the global marketing strategy for the first competitor to Viagra and influenced the product development to ensure maximum market value. In 2004, Cialis was awarded Best Brand Launch of the Year by the Pharmaceutical Marketing Congress.

In addition, Brown held a variety of other leadership roles of increasing responsibility within Lilly’s sales, marketing and product management departments, including serving as general manager for Lilly China, where he helped Lilly establish its presence. During his tenure as GM, he managed a joint venture in Suzhou, oversaw the construction of Lilly’s first manufacturing facility and expanded the affiliate’s reach from 12 to 45 cities. Notably, Brown also helped establish STC Corporation, a generic subsidiary for Lilly, and served as its first president.

Brown joined Lilly in 1985, after receiving a bachelor’s degree in economics from DePauw University and a master’s in business administration from Indiana University. Brown currently serves on the board of trustees of Franklin College.

Sanjeev Ahuja, MD, MBA, FACP

Chief Medical Officer

Sanjeev Ahuja, Chief Medical Officer

Sanjeev joins Brickell from a start-up biotechnology company focused on rare inflammatory diseases, Celtaxsys, where he was the Chief Medical Officer for five years and led all the clinical and regulatory activities as a member of the executive team.

He has almost 40 years of experience as a physician having specialized in obstetrics-gynecology and internal medicine. As a clinician he has practiced in diverse settings over 20 years including in the military, a rural hospital, private practice, and academia, most recently practicing at the University of Cincinnati.

He joined the industry almost 20 years ago starting at Lilly and then at Sanofi-Genzyme. Amongst the assignments at Lilly he led the establishment of a R&D joint venture company in India as the founding CEO and CMO. Before joining Celtaxsys he was the CMO at a start-up out of Purdue University, OnTarget Laboratories, focused on intra-operative imaging in cancer.

Sanjeev has experience in all phases of drug development from first-in-humans to Phase 3 leading to successful approval, and Phase 4 and health outcomes work. He has experience in regulatory activities around the globe including INDs and NDAs. He also has experience in fund raising for start-ups, due diligence, and managing industry partnerships.
He has worked across several therapeutic areas including urology,
women’s health, oncology, dermatology, and cystic fibrosis.
Sanjeev obtained his medical degree from the Armed Forces Medical College, Pune, India and has an MBA from the University of Cincinnati. He is board certified in internal medicine and is a Fellow of the American College of Physicians. He is licensed to practice medicine in Indiana.

Jose Breton

Chief Accounting Officer

Mr. Breton has served as Brickell’s Controller and Chief Accounting Officer since 2013. Prior to joining Brickell, Mr. Breton was an auditor from 2014 to 2015 at Deloitte LLP.

Mr. Breton began his career in 2012 as a Client Manager at Global Resource Partners, Inc., an accounting and business advisory firm. In this role, Mr. Breton had overall responsibility for clients’ financial reporting, planning and budgeting, systems of internal controls, corporate and benefits accounting and administration of stock option activity. Mr. Breton holds a B.B.A. degree in Accounting and Finance and a Master’s Degree in Taxation from the University of Miami.

R. Michael Carruthers

Chief Financial Officer

Mr. Carruthers has over 20 years of experience in serving as the Chief Financial Officer for publicly-traded pharmaceutical companies.

Mr. Carruthers previously served as Interim President of Nivalis Therapeutics (Nasdaq: NVLS) beginning in January 2017 and Chief Financial Officer and Secretary since February 2015. From December 1998 to February 2015, he served as Chief Financial Officer for Array BioPharma (Nasdaq: ARRY). Prior to this, his professional experience included Chief Financial Officer of Sievers Instrument, treasurer and controller for the Waukesha division of Dover Corporation and accountant with Coopers & Lybrand. Mr. Carruthers received a B.S. in accounting from the University of Colorado and a M.B.A. from the University of Chicago.

Deepak Chadha, M.S., MBA, RAC

Chief R & D Officer

With more than two decades of regulatory and clinical development experience in the Pharma, Biotech and Medical Device fields, Deepak Chadha is responsible for leading Brickell’s R&D organization.

Mr. Chadha's management experience encompasses providing strategic vision, leadership, and oversight to ensure the successful execution of global product development programs, including direct responsibility over the preclinical, CMC, quality, clinical and regulatory functions. Mr. Chadha has worked on various product development projects for drugs, biologics, medical devices and combination products, including marketing applications to the FDA, the EMA, as well as the regulatory agencies of the UK, Canada, Australia, and Japan among others, which resulted in the approval of several products that went on to become best-in-class within their respective areas.
Prior to Brickell, Mr. Chadha held the role of Vice President, Global Regulatory Affairs at Suneva Medical. During his time at Suneva Medical, Mr. Chadha led the regulatory approval for BELLAFILL® dermal filler for acne scar correction and supported the company’s commercial products life cycle management. Before Suneva, Mr. Chadha worked at Allergan (f.k.a. KYTHERA), where Mr. Chadha successfully led their lead product, KYBELLA®, from an early clinical phase to an NDA stage, and also supported the ex-US regulatory activities. Mr. Chadha also served as Vice President of Global Regulatory Affairs at Allergan Medical (f.k.a. Inamed Corporation), where he assisted in building the organization’s Global Regulatory Affairs department, and was involved with the approval for JUVEDERM®, Bioenterics®, LAP-BAND® and Silicone gel-filled Breast Implants. In addition, his career has included positions of increasing responsibility at Biomeasure Inc. (IPSEN) and Stryker Biotech.

Mr. Chadha holds a BS in Pharmaceutical Sciences from Berhampur University in Orissa, India, an MS in Pharmaceutics from Hamdard University in New Delhi, India, and an MBA in International Business from California State University, Dominguez Hills.

Adam Levy

Chief Business Officer

Adam Levy is the Chief Business Officer at Brickell Biotech.

Prior to joining Brickell, Mr. Levy served as Chief Business Officer at miRagen Therapeutics since 2016. Between 2000 through 2016, Mr. Levy held multiple Investment Banking positions at Merrill Lynch, Pierce, Fenner & Smith, Jefferies Group and Wedbush Securities.

Mr. Levy earned a B.S. in Applied Economics from Cornell University.

Andrew Sklawer

Co-Founder & Chief Operating Officer

Andy Sklawer has 15 years of experience in building and operating development-stage companies.

Prior to co-founding Brickell, he served as the Head of Operations at Concordia Pharmaceuticals, Inc., an oncology drug development company acquired by Kadmon Corporation in 2011. Prior to Concordia, Mr. Sklawer held various positions with increasing responsibility at Verid, Inc., a developer of security technology prior to and subsequent to its acquisition by EMC Corporation.

Mr. Sklawer holds a B.S. degree in Marketing from the University of Florida and received his M.B.A. from the University of Miami. Andy currently serves as a Board Member for StartUp FIU and on the Advisory Committee of the Advancing Innovation in Dermatology Accelerator Fund.

Gary Walker

Chief Marketing Officer

Gary brings 35+ years of marketing and general management experience to Brickell Bio as Chief Marketing Officer. Prior to joining Brickell, Gary spent 10 years at the Eli Lilly Company building and leading Global Brands and preparing them for successful launch. His experience spans multiple disease states - including Alzheimer’s Disease, Chronic Pain, and Depression. As a global marketing leader for Eli Lilly, Gary also had an opportunity to lead the Digital Innovation team in Japan, as well as make the company’s first Disease State Education TV advertisement in Japan.

Prior to Eli Lilly, Gary served the Steak n Shake Company (NYSE listed $1B+ revenues) as Senior Vice President, COO. In the 9 years Gary spent at Steak n Shake, he played a leading role in accelerating marketing, menu and service innovation. Gary also led the franchising business for Steak n Shake for 5 years.

Gary’s other previous marketing and general management experience includes 4 years with DowBrands and 14 years with Procter & Gamble. Over that period, Gary launched 10+ new innovative products across numerous brands like Scrubbing Bubbles, Tide, Cascade, Ivory, etc.

Gary has a BS Chemical Engineering from Bucknell University and has deep knowledge of Six Sigma, 4DX Execution, Service Profit Chain and Innovation/Design Thinking processes.

Herbert R. Brinkman, Ph.D.

Vice President, Chemistry, Manufacturing, and Controls

Dr. Brinkman brings more than 25 years of drug development experience in CMC activities ranging from early product development to commercial launch.

Prior to joining Brickell, Herb served as Director, Research and Development at KVK Tech where he oversaw the development of ophthalmic, injectable, and topical products. Previously, he was Vice President of Product Development at TOLMAR, Inc. where he was responsible for directing the formulation development, analytical development, and process engineering teams for TOLMAR’s topical dermatology and parenteral products. Prior to joining TOLMAR, Dr. Brinkman was a CMC a consultant for various small and midsize pharmaceutical companies specializing in the development of topical products. He was also Director of Product Development at Tapestry Pharmaceuticals, Inc. and NaPro BioTherapeutics, Inc. where he led the development of novel APIs and formulations in various therapeutic areas. Herb began is pharmaceutical career at Hoffmann-LaRoche, in the Pharmaceutical Process Development group, where he was involved in the development and scale up of 4 NDA products, including Xedola® (Capecitabine) and Rocaltrol® (Calcitriol).

Dr. Brinkman holds a BA in Chemistry from Rutgers University and a Ph.D. in Organic Chemistry from Seton Hall University.

Michael P. Doyle, Ph.D.

Vice President, Regulatory Affairs

Dr. Doyle has worked in the pharmaceutical industry for over 23 years with the last 15 years in Regulatory Affairs.

Prior to Brickell, Dr. Doyle served as Senior Director, Regulatory Affairs at Clovis Oncology where he was responsible for Regulatory Affairs strategy and operations in support of oncology clinical trials in the US, Canada, and the EU. Prior to joining Clovis, Dr. Doyle was Global Head of Regulatory Affairs at Novella Clinical, a clinical research organization specializing in oncology, where he was responsible for all aspects of regulatory support. Before Novella, Dr. Doyle held senior management positions in Regulatory Affairs at OSI Pharmaceuticals and Array BioPharma.

Before moving into Regulatory Affairs, Dr. Doyle held scientific positions with Somatogen and Baxter Healthcare, most recently serving as Senior Research Scientist supporting Baxter’s Hemoglobin Therapeutics program. Dr. Doyle holds a Ph.D. in physiology from the University of New Mexico School of Medicine and completed four years of post doctoral training at the University of Virginia Health Sciences Center.

David McAvoy, M.S.E.S., J.D.

General Counsel

David McAvoy joins Brickell Biotech as General Counsel. Prior to this, Dave served as General Counsel, Vice President and Chief Compliance Officer for the nuclear medicine and oncology biotech Endocyte, Inc., helping it to be acquired successfully by Novartis AG for $2.1 billion in December 2018.

Before Endocyte, Mr. McAvoy was at Eli Lilly and Company for 27 years including as General Counsel of Lilly Emerging Markets – at the time, a $3 billion company division – and most recently there in an executive management business role running strategic alliances for the food animal production group at Lilly’s former Elanco Animal Health subsidiary, now spun off. Also at Lilly, Mr. McAvoy was lead counsel for several iconic medicines, including Prozac® for depression, Gemzar® for pancreatic and lung cancers, and ReoPro®, one of the first interventional cardiology agents. While there he partnered with FDA to create important policy precedents in orphan drug, direct-to-consumer advertising of pharmaceuticals, and clinical trial transparency that influence the industry favorably today.

Mr. McAvoy earned a J.D. and Master of Science in Environmental Science with highest honors from Indiana University, and a B.A. in political science from the University of Notre Dame. He serves on the Board of Directors for The Villages of Indiana, Inc., championing families for abandoned and abused children.

Ginger McWilliams

Vice President, Professional Relations and New Product Planning

Ginger joined Brickell with extensive experience which includes 22 years of pharmaceutical/ biotech/marketing experience across hospital marketing and three of the most successful pharmaceutical companies in the world: Novartis, Johnson and Johnson, and Lilly. She has expertise in pre-launch and commercialization efforts notably with both small and large molecules with a specialty in dermatology.

With her experience, a gamut of leadership roles in sales, market access, marketing, training and professional relations helped launch some of the most commercially successful dermatologic compounds including Lamisil, Remicade, Stelara, and most recently Taltz.

Nancy Seretta

Vice President, Head of Clinical Operations

Nancy brings more than 20 years of experience in the area of clinical operations management, providing consulting services to several pharmaceutical, biotech and medical device companies, with a specialization in the dermatology space. She has worked on Phase 1 through 4 studies encompassing small molecules, biologics, medical devices and combination products.

Over the last three years she has been actively supporting Brickell’s clinical operations projects related to the sofpironium bromide (SB) clinical development program, starting with the Phase 2b study, the on-going long-term safety study and leading the planning and initiation of Phase 3 studies later this year. Nancy is leading the efforts for SB P3 clinical studies.


Reginald Hardy, R.Ph., MBA

Co-Founder and Chairman of the Board of Directors

Mr. Hardy has over 25 years of experience in serving as the Chief Executive Officer and/or President for publicly-traded and privately-held pharmaceutical companies.

Prior to Brickell, Reginald was the co-founder and President of Concordia Pharmaceuticals, Inc. an oncology drug development company acquired by Kadmon Corporation in 2011. Mr. Hardy was co-founder and President of SANO Corporation, a pharmaceutical company focused on the development of novel transdermal drug delivery systems that was acquired by Elan Corporation. Prior to SANO, Mr. Hardy served as the President of the generics group at IVAX Corporation. Reginald has also held various corporate roles with Hoechst-Roussel Pharmaceuticals, Inc. and Key Pharmaceuticals, Inc. Mr. Hardy earned his B.S. degree in Pharmacy from the University of North Carolina—Chapel Hill and M.B.A. from UNC-Greensboro.

George B. Abercrombie, R.Ph., MBA


Mr. Abercrombie served as President and Chief Executive Officer at Hoffmann-La Roche Incorporated from 2001-2009 where he was responsible for leading the North American Pharmaceuticals Operations and the Canadian affiliate, Hoffmann-La Roche Ltd.

Before joining Roche, Mr. Abercrombie was Senior Vice President of U.S. commercial operations at Glaxo Wellcome, with responsibilities encompassing pharmaceutical sales and marketing, electronic commerce, the U.S. managed care system, disease management, business planning and development, and late-stage clinical drug studies. He joined Glaxo as Vice President and General Manager of the Glaxo Pharmaceuticals Division in 1993 following 10 years at Merck, where he held a broad range of positions in sales, marketing, executive sales management and business development.

Mr. Abercrombie began his career as a pharmacist after receiving a bachelor’s degree in pharmacy from the University of North Carolina at Chapel Hill. He later earned an M.B.A. from Harvard University.

Gary A. Lyons


Mr. Lyons held various positions with Neurocrine Biosciences, Inc., a biopharmaceutical company, for 16 years through January 2008, including President, Chief Executive Officer and member of the board of directors. From 1983 to 1993, Mr. Lyons held various executive positions at Genentech, Inc., a biotechnology company, including Vice President of Business Development, Vice President of Sales, and Director of Sales and Marketing. Mr. Lyons presently serves as a member of the board of directors of Neurocrine Biosciences, Inc. and Novus Therapeutics, Inc. (Nasdaq: NVUS) and is chairman of the board of directors of Rigel Pharmaceuticals, Inc. and Retrophin, Inc., all of which are publicly held biotechnology companies. In addition, Mr. Lyons served previously on the board of directors of PDL BioPharma, Facet Biotech Corporation, KaloBios Pharmaceuticals, Inc. and NeurogesX, Inc. Mr. Lyons holds a bachelor’s degree in marine biology from the University of New Hampshire and an M.B.A. degree from Northwestern University, JL Kellogg Graduate School of Management. Mr. Lyons’ extensive managerial experience, including his role as a Chief Executive Officer and other executive level positions at public and private companies in the biotechnology sector provide him with the qualifications and skills to serve on the combined company’s board of directors.

Vijay B. Samant


Mr. Samant served as President and Chief Executive Officer of Vical since November 2000. Prior to joining Vical, he had 23 years of diverse U.S. and international sales, marketing, operations, and business development experience with Merck. From 1998 to 2000, he was Chief Operating Officer of the Merck Vaccine Division. From 1990 to 1998, he served in the Merck Manufacturing Division as Vice President of Vaccine Operations, Vice President of Business Affairs and Executive Director of Materials Management. Mr. Samant holds a master’s degree in management studies from the Sloan School of Management at MIT, a master’s degree in chemical engineering from Columbia University, and a bachelor’s degree in chemical engineering from the University of Bombay, University Department of Chemical Technology. Mr. Samant was a member of the board of directors of AmpliPhi Biosciences Corporation from 2015 to 2019, a member of the board of directors of Raptor Pharmaceutical Corporation from 2011 to 2014, and a member of the board of directors for BioMarin Pharmaceutical Inc. from 2002 to 2004. Mr. Samant was a Director of the Aeras Global TB Vaccine Foundation from 2001 to 2010, a member of the Board of Trustees for the National Foundation for Infectious Diseases from 2003 to 2012, and a member of the Board of Trustees for the International Vaccine Institute in Seoul, Korea from 2008 to 2012. Mr. Samant’s extensive expertise in biopharmaceutical development and product commercialization, as well as his strong technical and entrepreneurial experience in diverse fields provide him with the qualifications and skills to serve on the combined company’s board of directors.

Dennison (Dan) T. Veru


Mr. Veru is a Principal of Palisade Capital and a member of the Investment Policy Committee. Mr. Veru has oversight responsibilities for all the investment strategies at Palisade Capital involving publicly traded securities.

From 1992 through 1999, Mr. Veru was the President and Director of Research at Awad Asset Management and helped oversee the firm's growth from start up to more than one billion of small cap institutional and high net worth assets.

Prior to Awad, Mr. Veru became associated with the partners of Palisade in 1984 at Drexel Burnham Lambert and later at Smith Barney Harris Upham where he held a variety of analytical roles.

In addition to his professional responsibilities, Mr. Veru is a member of the Board of Overseers of the St. Lukes and Roosevelt hospital, a member of the finance committee of the Dwight-Englewood School, and a member of the Board of the McCarton School for autistic children. A graduate of Franklin & Marshall College in 1983, Mr. Veru is a frequent guest on CNBC, Bloomberg News, Fox News and CNN. He also contributes market opinions to various financial publications.


Charles W. Stiefel

Chairman of Advisory Board

Prior to joining Brickell, Mr. Stiefel was chairman and CEO of Stiefel Laboratories, Inc. Founded in 1847, Stiefel Laboratories was a family-owned company for more than 160 years until it was sold to GlaxoSmithKline in 2009. At the time, Stiefel Laboratories was the world's largest privately held pharmaceutical company specializing in dermatological products, with nearly 4,000 employees in more than 30 countries and products distributed in more than 100 countries. Charles first joined the company as general counsel in 1982 and was subsequently named executive vice president and then president.

In 2003, Mr. Stiefel was awarded a Lifetime Achievement Award by the South Florida Dermatology Foundation, and in 2006 he was named Ernst & Young's Entrepreneur of the Year in Health Sciences for the state of Florida.

Born in Catskill, New York, Mr. Stiefel holds an undergraduate degree from Yale University and a JD degree from Albany Law School.

Victor J. Bauer, Ph.D.

Scientific Advisor

Dr. Bauer has more than 35 years of pharmaceutical product development and management experience with extensive US and international pharmaceutical businesses. He has a broad background in research, pre-clinical and clinical development, regulatory aspects of drug and biologics approval, intellectual property management, licensing, and executive management. Dr. Bauer was most recently Executive Vice President and Chief Scientific Officer at Concordia Pharmaceuticals, Inc. Prior to Concordia, Dr. Bauer was previously President of Hoechst-Roussel Pharmaceuticals, Inc. (Aventis). Dr. Bauer also serves as a Board Director at Titan Pharmaceuticals.

Charles J. Betlach, II, Ph.D.

Drug Development Advisor

Dr. Betlach is a long-time veteran in the pharmaceutical industry. Dr. Betlach served as Brickell’s Vice President, New Product Development from inception until his retirement in 2017. Prior to Brickell, Dr. Betlach was a Director of Concordia Pharmaceuticals, Inc. and a private investor. From 1991–1998, Dr. Betlach was co-founder and Executive Vice President, Research and Development of SANO Corporation. Prior to SANO, Dr. Betlach held various senior research positions at Key Pharmaceuticals, Inc. and Schering-Plough Corporation.

Dr. Betlach has an MS degree in Cellular Biology from the University of California Santa Barbara and a PharmD in Pharmacy and a PhD in Pharmaceutical Chemistry from the University of California San Francisco and has spent a number of years in academia before moving to the pharmaceutical industry. Dr. Betlach has over 25 publications in peer-reviewed journals in different areas of molecular biology, pharmacogenetics, drug discovery and clinical studies.

Laurie Beth Burke, MPH

Regulatory Advisor

Laurie Burke is the Founder of LORA Group, LLC, and provides expert consultation to global medical product development organizations regarding best practices in patient-focused drug development, outcomes research, regulatory strategy, product labeling and advertising. Her primary interest is the development and incorporation of state of the science measures as clinical trial endpoints. She was a career US Public Health Service officer with the US Food and Drug Administration, Center for Drug Evaluation and Research, where she maintained regulatory policy development and oversight responsibilities related to labeling and outcomes measurement in clinical trials.

She was the lead author of the FDA Patient-Reported Outcomes Guidance published as draft in 2006 and final in 2009. She collaborated extensively on matters of PRO measurement with the European Medicines Agency, the National Institutes of Health, other US Department of Health and Human Services agencies. She is an Affiliate Associate Professor at the University of Maryland School of Pharmacy and a past International Society for Pharmacoeconomics and Outcomes Research Board Member. Her academic degrees include a Master of Public Health in Epidemiology from the Uniformed Services University of the Health Sciences and a bachelor of science in pharmacy from the University of Kansas.

James Tanenbaum, J.D.

Legal and Business Advisor

James (Jim) Tanenbaum concentrates on corporate finance and the structuring of complex domestic and international capital markets transactions. He has represented issuers, including some of the nation's largest financial institutions, underwriters, agents and other financial intermediaries, in public and private offerings of securities as well as issuers, investment banks and purchasers in hybrid, mortgage-related and derivative securities transactions. He has developed some of the most widely used hybrid techniques for the placement and distribution of securities.

Jim has worked closely with leading investment banks to formulate new methodologies for securities offerings and to structure innovative financial products. He has also represented many technology-based companies, including biotech and medical device companies.

Jim is a frequent lecturer on capital markets topics, and has lectured at the Securities and Exchange Commission, SIFMA and at a variety of securities industry groups. He has lectured at law schools both in the United States and abroad. He is the co-author of Covered Bonds Handbook, published by Practising Law Institute (2010, updated 2012-2014), co-author of the treatise Exempt and Hybrid Securities Offerings, published by Practising Law Institute (2009, second ed. 2011, updated 2014, third ed. 2017) and also co-author of BNA Tax and Accounting Portfolio, SEC Reporting Issues for Foreign Private Issuers (BNA Accounting Policy and Practice Series, 2009, second ed. 2012, updated 2016). Additionally, Jim co-authored ``Regulation of Financial Institutions, Financial Crises and Rescue Packages in Europe: the Iceland Case,`` a chapter in Global Financial Crisis (Globe Law and Business, 2009) and ``The Law: Legal and Regulatory Framework,`` a chapter in PIPEs: A Guide to Private Investments in Public Equity (Bloomberg, 2006).

Jim was cited as a recommended lawyer for capital markets in the IFLR1000 Guide to Leading Lawyers, as one of America's leading lawyers for capital markets–debt and equity by Chambers USA and Chambers Global, and as a recommended lawyer for capital markets–debt and equity transactions by The Legal 500 US.

During Jim's time in law school, he served as an Editor of the University of Pennsylvania Law Review. He also served as Chairman of the Board of Trustees of Lehigh University and as National Chair of the Benjamin Franklin Society of the University of Pennsylvania.

William H. Eaglstein, M.D.

Dermatology Advisor

Dr. Eaglstein is past professor and chairman of dermatology at the University of Pittsburgh and at the University of Miami, where he is currently chairman emeritus. Since 2004 he has worked in industry at Ivax Pharmaceuticals (President of Ivax Derm), Teva and Stiefel Pharmaceuticals ( Vice President of Research ) and Stiefel a GSK company (Vice President of New Product Assessment and External Research).

He is currently an independent consultant and serves as a volunteer advisor for the Stanford School of Medicine SPARK program. His medical/scientific interests include wound healing, drug development, skin infections, UV inflammation and inflammatory diseases such as psoriasis and acne. Dr. Eaglstein has been a Robert Wood Johnson Health Policy Fellow, Chairman of an FDA skin advisory panel and on the National Institute of Arthritis, Musculoskeletal and Skin Diseases Advisory Panel. He continues his interest in health and regulatory policy. His hobbies include contemporary art and bicycling. He resides with his wife, Janet, in Menlo Park, California.

Andrew Hirschberg

Investment Banker

Head of Investment Banking, Triad Securities Corp., Andy is focused on M&A and Strategic life science transactions with a focus on the specialty pharmaceutical sector. Prior to joining Triad Securities, he was a Managing Director at Roberts Mitani, LLC from July 2011 through December 2013. From May 1984 through June 2011, Andy served as President of Corporate Development Specialists Inc., a firm which provided advisory services to pharmaceutical, device, consumer and biomedical companies.

During the past three decades, Andy has worked with clients on a variety of merger, acquisition and product licensing agreements and has successfully consummated over 100 transactions, with an aggregate value exceeding $5 Billion. Andy has particular expertise in dermatology, where he has been the lead advisor on more than forty consummated transactions. Andy received a B.A. from Colgate University, a Masters in accounting from NYU Stern School of Business, and an MBA from University of Chicago Graduate School of Business.

David M. Pariser, M.D.

Dermatology Advisor

Dr. David Pariser is an active dermatologist and a founding board member of the International Hyperhidrosis Society (IHHS). He is a professor in the Department of Dermatology at Eastern Virginia Medical School in Norfolk, Virginia, where he is also the senior physician with Pariser Dermatology Specialists, Ltd., a private group practice of 12 Dermatologists, 7 Physician Assistants and 1 Nurse Practitioner. Dr. Pariser has been an American Academy of Dermatology (AAD) fellow since 1977 and was elected 2009-2010 president of the AAD (which represents more than 16,000 member physicians worldwide). Additionally, Dr. Pariser is an internationally renowned speaker on a variety of dermatologic issues and has participated in over 350 funded clinical trials.

Dr. Pariser has treated hundreds of hyperhidrosis patients and has lectured about the mechanism, diagnosis, and treatment of hyperhidrosis at numerous professional education forums on behalf of the IHHS, the AAD, and other dermatological associations. He is the consummate researcher and is continuously pursuing new treatment methods that will improve the quality of life of his patients. Dr. Pariser feels that, in his 37 years of practice, the patients who have given him the most inspiration are the hyperhidrosis sufferers whose lives he has been able to improve.

Stacy R. Smith, M.D.

Clinical Advisor

Dr. Stacy R. Smith is a US board-certified dermatologist with over 20 years of experience in dermatology, dermatologic research and product development. Dr. Smith has performed over 200 clinical research studies in dermatology for a broad range of conditions including psoriasis, acne, hyperhidrosis, atopic dermatitis, precancerous and cancerous skin conditions as well as numerous aesthetic therapies. He was pivotal in the US approval of Restylane, Botox Cosmetic, Juvederm, Dysport, Adalimumab, Ustekinumab and la Viv among many others.

Dr. Smith has served as a consultant to industry for more than 10 years including medical monitoring positions, FDA panel presentations and meetings with regulatory authorities in the US and abroad.
Dr. Smith has authored more than 50 scientific articles and frequently lectures at various professional meetings and societies including the American Academy of Dermatology, the American Society of Dermatologic Surgery and the American Society for Laser Medicine and Surgery as well as the US FDA. He is an Associate Clinical Professor in the Division of Dermatology at the University of California, San Diego.

Dr. Smith earned his medical degree from Drexel University in Philadelphia, where he won several awards including election to the Alpha Omega Alpha medical honor society. He served as a member of the US Naval Medical Corps, serving with the US Marines and subsequently completed his specialty training in Dermatology at the Naval Medical Center in San Diego.


Kaken Pharmaceutical Co., Ltd.

Currently developing Sofpromium Bromide For Hyperhidrosis

Exclusive License — Mar.2015

Kaken (Tokyo Stock Exchange 4521) is a Japanese specialty pharmaceutical company with a strong presence in the market of dermatology (antifungals) and orthopedics. The company’s primary areas of R&D focus include inflammation, immunology (dermatitis, rheumatoid arthritis, and osteoarthritis) pain and antifungals.